Did your U.S. Representative decide to protect women and babies from the dangers of the abortion pill?

Call your Representative to say thank you or express your disappointment now!

175 Members of Congress have called for an immediate investigation into the safety of mifepristone (the abortion pill) and are urging the reinstatement of in-person dispensing requirements. See Restoration of America Foundation’s press release.
 
Here’s what you need to know:
 
  • A recent study from Restoration of America Foundation shows that 1 in 10 women experience serious adverse events like sepsis, infection, or hemorrhaging after taking mifepristone—22 times higher than FDA estimates
  • The Biden administration removed in-person doctor visit requirements in 2023, allowing these drugs to be mailed without medical oversight
  • Abortion drugs now account for nearly two-thirds of all abortions in America—over 600,000 annually
  • 70% of voters agree it makes sense to restore safety standards requiring in-person dispensing

What You Can Do

Contact your Member of Congress today and urge them to:
  1. Say thanks for signing the letter or express your disappointment in them not signing it NOW!
  2. Support the investigation into mifepristone safety concerns
  3. Call for the reinstatement of in-person dispensing requirements
  4. Demand expedited FDA review of abortion drug dangers
If Your Representative SIGNED the Letter (one of the 175):
What to Say: “I’m calling to thank Representative [NAME] for signing the letter calling for an investigation into abortion pill safety and for demanding the reinstatement of in-person dispensing requirements. I appreciate their commitment to protecting women’s health and ensuring proper medical oversight. This is exactly the kind of leadership we need.”
 
If Your Representative DID NOT Sign the Letter:
What to Say: “I’m calling to express my disappointment that Representative [NAME] has not yet joined the 175 Members of Congress calling for an investigation into abortion pill safety. Recent research shows that 1 in 10 women experience serious adverse events from this drug—22 times more than the FDA acknowledges. I’m concerned that my representative isn’t prioritizing women’s health and safety. I urge them to support this investigation and the reinstatement of in-person dispensing requirements immediately.”

Find your Representative's phone number below:

Alabama
[wpdatatable id=7]
Alaska

[wpdatatable id=5]

Arizona

[wpdatatable id=11]

Arkansas

[wpdatatable id=8]

California

[wpdatatable id=9]

Colorado

[wpdatatable id=10]

Florida

[wpdatatable id=14]

Georgia

[wpdatatable id=15]

Idaho

[wpdatatable id=16]

Illinois

[wpdatatable id=17]

Indiana

[wpdatatable id=18]

Iowa

[wpdatatable id=19]

Kansas

[wpdatatable id=20]

Kentucky

[wpdatatable id=21]

Louisiana

[wpdatatable id=22]

Maryland

[wpdatatable id=23]

Michigan

[wpdatatable id=24]

Minnesota

[wpdatatable id=25]

Mississippi

[wpdatatable id=26]

Missouri

[wpdatatable id=27]

Montana

[wpdatatable id=28]

Nebraska

[wpdatatable id=29]

Nevada

[wpdatatable id=30]

New Jersey

[wpdatatable id=31]

New York

[wpdatatable id=32]

North Carolina

[wpdatatable id=33]

North Dakota

[wpdatatable id=34]

Ohio

[wpdatatable id=35]

Oklahoma

[wpdatatable id=36]

Oregon

[wpdatatable id=37]

Pennsylvania

[wpdatatable id=38]

South Carolina

[wpdatatable id=39]

South Dakota

[wpdatatable id=40]

Tennessee

[wpdatatable id=41]

Texas

[wpdatatable id=42]

Utah

[wpdatatable id=43]

Virginia

[wpdatatable id=44]

Washington

[wpdatatable id=45]

West Virginia

[wpdatatable id=46]

Wisconsin

[wpdatatable id=48]

Wyoming

[wpdatatable id=47]